<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02792764</url>
  </required_header>
  <id_info>
    <org_study_id>BPV-13-003</org_study_id>
    <nct_id>NCT02792764</nct_id>
  </id_info>
  <brief_title>Post-Marketing Study to Assess Complication Rates of Oncology Patients With Ports and Peripheral IVs</brief_title>
  <acronym>VEINSFORLIFE</acronym>
  <official_title>A Prospective, Multi-centered Study to Assess the Complication Rates of Oncology Patients Accessed With Peripheral Intravenous Lines Versus Implantable Ports for Chemotherapy Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to collect current information on complications rates of subjects undergoing
      chemotherapy administration through Ports and peripheral IVs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of adverse events in subjects undergoing chemotherapy administration through PORTs and PIVs.</measure>
    <time_frame>Through end of chemotherapy, up to 3 years</time_frame>
    <description>Subjects medical records will be retrospectively reviewed from present day back to January 1, 2008 to assess for complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The average number of accesses during course of treatment (i.e. - chemotherapy administration, CTs, blood draws, TPN, etc.)</measure>
    <time_frame>Through end of chemotherapy, up to 3 years</time_frame>
    <description>Subjects medical records will be retrospectively reviewed from present day back to January 1, 2008 to assess for complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of Vascular Access Device conversion from Peripheral IV to PORT</measure>
    <time_frame>Through end of chemotherapy, up to 3 years</time_frame>
    <description>Subjects medical records will be retrospectively reviewed from present day back to January 1, 2008 to assess for complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The average time of vascular access device conversion from Peripheral IV to PORT</measure>
    <time_frame>Through end of chemotherapy, up to 3 years</time_frame>
    <description>Subjects medical records will be retrospectively reviewed from present day back to January 1, 2008 to assess for complications</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>PORTs/Peripheral IVs Complication Rates</condition>
  <arm_group>
    <arm_group_label>Port</arm_group_label>
    <description>Subjects receiving chemotherapy through a port</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peripheral Intravenous (PIV) Lines</arm_group_label>
    <description>Subjects receiving chemotherapy through a peripheral IV</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects who are currently undergoing or has had infusional cancer therapy (solid tumor
        or hematologic) through a Bard PORT with a distally-valved catheter/open-ended catheter or
        infusion through a Peripheral IV
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age â‰¥ 21 years

          -  Subject is currently undergoing or has had infusional cancer therapy (solid tumor or
             hematologic) through a Bard PORT with a distally-valved catheter/open-ended catheter
             or infusion through a PIV

          -  Subject had a chemotherapy regimen consisting of a vesicant and/or irritant

          -  Subject has signed an Informed Consent Form (ICF) or has had an ICF signed by the
             subject's legally authorized representative

        Exclusion Criteria:

          -  Subject has/had an implanted non Bard PORT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quincy Medical Group</name>
      <address>
        <city>Quincy</city>
        <state>Illinois</state>
        <zip>62301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willis Knighton Cancer Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2014</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <last_update_submitted>June 6, 2016</last_update_submitted>
  <last_update_submitted_qc>June 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>port</keyword>
  <keyword>peripheral intravenous lines</keyword>
  <keyword>oncology</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

